CAM
ENGN icon

Cormorant Asset Management’s enGene Therapeutics ENGN Stock Holding History

Cormorant Asset Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,000,000
Closed -$36.1M – 48
2025
Q4 		$36.1M Buy
4,000,000
+1,676,405
+72% +$13.4M 1.67% 15
2025
Q3 		$15.9M Hold
2,323,595
– – 1.1% 23
2025
Q2 		$8.46M Hold
2,323,595
– – 0.63% 30
2025
Q1 		$10.4M Hold
2,323,595
– – 0.78% 29
2024
Q4 		$15.5M Buy
2,323,595
+1,323,595
+132% +$10.3M 0.85% 30
2024
Q3 		$6.6M Hold
1,000,000
– – 0.35% 38
2024
Q2 		$9.43M Hold
1,000,000
– – 0.54% 36
2024
Q1 		$16.9M Buy
+1,000,000
New +$12.2M 0.74% 36

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Cormorant Asset Management's ENGN Position: Q1 2026 in Review

Cormorant Asset Management sold out of enGene Therapeutics (ENGN) in Q1 2026, closing a stake of 4,000,000 shares — an estimated $36.1M sold.

Cormorant Asset Management first reported a position in ENGN in Q1 2024 and held it in 8 quarters. The position peaked at $36.1M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • Cormorant Asset Management reported no remaining enGene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cormorant Asset Management sold 4,000,000 enGene Therapeutics shares in Q1 2026, an estimated $36.1M.
  • Cormorant Asset Management first reported a position in enGene Therapeutics in Q1 2024 and held it in 8 quarters.
  • Cormorant Asset Management's enGene Therapeutics position peaked at $36.1M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on Cormorant Asset Management's 13F filing for Q1 2026, filed 15 May 2026.